CD176 antiserum treatment leads to a therapeutic response in a murine model of leukemia

Yi,Bin; Zhang,Zhe; Zhang,Min; Schwartz-Albiez,Reinhard; Cao,Yi

doi:10.3892/or.2013.2639

CD176 antiserum treatment leads to a therapeutic response in a murine model of leukemia

Authors:
- Bin Yi
- Zhe Zhang
- Min Zhang
- Reinhard Schwartz-Albiez
- Yi Cao
View Affiliations

Affiliations: Laboratory of Molecular and Experimental Pathology, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, P.R. China, Translational Immunology Unit, German Cancer Research Center, Heidelberg, Germany
Published online on: July 25, 2013 https://doi.org/10.3892/or.2013.2639
Pages: 1841-1847

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

CD176 (Thomsen-Friedenreich antigen) is a tumor-associated carbohydrate structure. CD176 is expressed at the surface of human leukemic cells but is almost absent in normal and benign adult human tissues. Therefore, CD176 could be a promising target for antitumor immunotherapy. In the present study, pre-immunization with asialoglycophorin A (containing the CD176 oligosaccharide chains) was able to significantly improve the survival time of mice carrying CD176+ leukemia as compared to the control mice without the immunization. Furthermore, the passive transfer of CD176 antiserum which reacted only with the tumor-associated CD176 in cancer cells, was able to effectively prolong the survival time of CD176+ leukemia mice. In particular, the CD176 antiserum treatment could inhibit the growth and spreading of CD176+ leukemic cells in bone marrow, spleen, liver, and lung as evidenced by histopathological examination. CD176 antiserum could induce the apoptosis of CD176+ leukemic cells in vivo in a manner as previously observed in vitro. The data provided strong evidence that both CD176 antigen-based active immunotherapy and CD176 antibody-based passive immunotherapy lead to a therapeutic response in CD176+ leukemia mice. Therefore, both CD176 vaccine and CD176 antibody drug may be beneficial for the treatment of CD176+ leukemia patients.

View Figures

View References

1	Goletz S, Cao Y, Danielcyk A, Ravn P, Schoeber U and Karsten U: Thomsen-Friedenreich antigen: the ‘hidden’ tumour antigen. Adv Exp Med Biol. 535:147–162. 2003.
2	Cao Y, Merling A, Karsten U and Schwartz-Albiez R: Expression of Thomsen-Friedenreich-related carbohydrate antigens on human leukemia cells. Leucocyte Typing VII. Mason D, et al: Oxford University Press; Oxford: pp. 204–205. 2002
3	Cao Y, Stosiek P, Springer GF and Karsten U: Thomsen-Friedenreich-related carbohydrate antigens in normal adult human tissues: a systematic and comparative study. Histochem Cell Biol. 106:197–207. 1996. View Article : Google Scholar : PubMed/NCBI
4	Springer GF: T and Tn, general carcinoma autoantigens. Science. 224:1198–1206. 1984. View Article : Google Scholar : PubMed/NCBI
5	Springer GF: Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med. 75:594–602. 1997. View Article : Google Scholar : PubMed/NCBI
6	Aller CT, Kucuk O, Springer GF and Gilman-Sachs A: Flow cytometric analysis of T and Tn epitopes on chronic lymphocytic leukemia cells. Am J Hematol. 52:29–38. 1996. View Article : Google Scholar : PubMed/NCBI
7	Kaspers GJ, Veerman AJ, Van Wering ER, et al: Prognostic significance of peanut agglutinin binding in childhood acute lymphoblastic leukemia. Leukemia. 10:675–681. 1996.PubMed/NCBI
8	Veerman AJ, Hogeman PH, Huismans DR, Van Zantwijk CH and Bezemer PD: Peanut agglutinin, a marker for T-cell acute lymphoblastic leukemia with a good prognosis. Cancer Res. 45:1890–1893. 1985.PubMed/NCBI
9	Lin WM, Karsten U, Goletz S, Cheng RC and Cao Y: Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells. Int J Exp Pathol. 92:97–105. 2011. View Article : Google Scholar : PubMed/NCBI
10	Cao Y, Karsten UR, Liebrich W, Haensch W, Springer GF and Schlag PM: Expression of Thomsen-Friedenreich-related antigens in primary and metastatic colorectal carcinomas. A reevaluation. Cancer. 76:1700–1708. 1995. View Article : Google Scholar : PubMed/NCBI
11	Glinsky VV, Glinsky GV, Rittenhouse-Olson K, et al: The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res. 61:4851–4857. 2001.PubMed/NCBI
12	Heimburg J, Yan J, Morey S, et al: Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11. Neoplasia. 8:939–948. 2006. View Article : Google Scholar : PubMed/NCBI
13	Cao Y, Merling A, Karsten U, et al: Expression of CD175 (Tn), CD175s (sialosyl-Tn) and CD176 (Thomsen-Friedenreich antigen) on malignant human hematopoietic cells. Int J Cancer. 123:89–99. 2008. View Article : Google Scholar : PubMed/NCBI
14	MacLean GD, Bowen-Yacyshyn MB, Samuel J, et al: Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J Immunother. 11:292–305. 1992. View Article : Google Scholar
15	Slovin SF, Ragupathi G, Musselli C, et al: Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Cancer Immunol Immunother. 54:694–702. 2005. View Article : Google Scholar
16	Dougan M and Dranoff G: Immune therapy for cancer. Annu Rev Immunol. 27:83–117. 2009. View Article : Google Scholar
17	Yi B, Zhang M, Schwartz-Albiez R and Cao Y: Mechanisms of the apoptosis induced by CD176 antibody in human leukemic cells. Int J Oncol. 38:1565–1573. 2011.PubMed/NCBI
18	Shigeoka H, Karsten U, Okuno K and Yasutomi M: Inhibition of liver metastases from neuraminidase-treated colon 26 cells by an anti-Thomsen-Friedenreich-specific monoclonal antibody. Tumor Biol. 20:139–146. 1999. View Article : Google Scholar
19	Karsten U, Butschak G, Cao Y, Goletz S and Hanisch FG: A new monoclonal antibody (A78-G/A7) to the Thomsen-Friedenreich pan-tumor antigen. Hybridoma. 14:37–44. 1995. View Article : Google Scholar : PubMed/NCBI
20	Topalian SL, Weiner GJ and Pardoll DM: Cancer immunotherapy comes of age. J Clin Oncol. 29:4828–4836. 2012. View Article : Google Scholar
21	Xu Y, Gendler SJ and Franco A: Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas. J Exp Med. 199:707–716. 2004. View Article : Google Scholar : PubMed/NCBI
22	Butschak G and Karsten U: Isolation and characterization of thomsen-friedenreich-specific antibodies from human serum. Tumor Biol. 23:113–122. 2002. View Article : Google Scholar : PubMed/NCBI
23	Maloney DG: Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med. 366:2008–2016. 2012. View Article : Google Scholar : PubMed/NCBI
24	Schwartz-Albiez R: Naturally occurring antibodies directed against carbohydrate tumor antigens. Adv Exp Med Biol. 750:27–43. 2012. View Article : Google Scholar : PubMed/NCBI
25	Glinskii OV, Sud S, Mossine VV, et al: Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-L-leucine. Neoplasia. 14:65–73. 2012.PubMed/NCBI